We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

2301:TWSELite-On Technology Corp. Analysis

Data as of 2026-03-14 - not real-time

NT$167.00

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Lite-On Technology (2301.TW) is trading at TWD 167, just shy of its 20‑day SMA of 168.8 and aligned with the 50‑day SMA, indicating a near‑term price plateau. The RSI of 50.8 signals a neutral momentum, while the MACD remains bearish with a negative histogram, and volume is trending down, suggesting short‑term pressure.
Fundamentally, the stock appears reasonably priced versus peers, with a trailing PE of 25.3 versus the industry average of 33.7 and a forward PE of 14.2, pointing to earnings acceleration. The dividend yield of 4.49% and a payout ratio of 68% are supported by robust cash (TWD 80.9 bn) and manageable debt (TWD 24.3 bn). Analysts project a 23% upside to the DCF‑derived fair value of TWD 63, but the current market price suggests the stock may be overvalued relative to intrinsic calculations. Overall, the blend of solid cash flow, attractive yield, and growth catalysts in data‑center and automotive segments supports a medium‑term buying case, while technical indicators counsel caution in the immediate term.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Bearish MACD histogram indicating downward momentum
  • Price slightly below the 20‑day SMA
  • Decreasing trading volume

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Forward PE of 14.2 suggests accelerating earnings
  • Dividend yield of 4.5% backed by strong cash generation
  • Analyst upside potential of ~23% to target price

Long Term

> 3 years
Positive
Model confidence: 7/10

Key Factors

  • Diversified exposure to data‑center, automotive and smart‑life solutions
  • Stable ROE (~16.7%) and consistent free cash flow
  • Sustainable dividend policy with solid balance sheet

Key Metrics & Analysis

Financial Health

Revenue Growth15.80%
Profit Margin9.10%
P/E Ratio25.3
ROE16.71%
ROA5.10%
Debt/Equity27.04
P/B Ratio4.2
Op. Cash FlowNT$14.5B
Free Cash FlowNT$3.3B
Industry P/E33.7

Technical Analysis

TrendBullish
RSI50.8
SupportNT$146.00
ResistanceNT$200.00
MA 20NT$168.80
MA 50NT$167.00
MA 200NT$146.25
MACDBearish
VolumeDecreasing
Fear & Greed Index72.88

Valuation

Fair ValueNT$63.28
Target PriceNT$206.11
Upside/Downside23.42%
GradeOvervalued
TypeBlend
Dividend Yield4.49%

Risk Assessment

Beta0.66
Volatility66.71%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.